Comparing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI)

Aadi Bioscience (NASDAQ:AADI) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aadi Bioscience and Actinium Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0	0	0	0	0.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 207.69%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Aadi Bioscience.

Risk & Volatility

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.

Earnings and Valuation

This table compares Aadi Bioscience and Actinium Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07 million	2.66	-$65.76 million	($2.35)	-1.15
Actinium Pharmaceuticals	$90,000.00	450.61	-$48.82 million	($1.10)	-1.18

Actinium Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aadi Bioscience and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Insider & Institutional Ownership

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Actinium Pharmaceuticals beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.